Prostate Specific Antigen (PSA)

Prostate Cancer Screening: Moving Beyond PSA

Robert G. Uzzo, MD, FACS May 01, 2012

More than 1 million prostate biopsies are performed annually in the United States, predominantly driven by elevations in PSA.

After Radical Prostatectomy, Patient Learns He Never Had Prostate Cancer

Ann W. Latner, JD May 01, 2012

Dr. B, 57, was a urologist with a busy private practice. One of his patients was Mr. O, 69, who had an abnormal PSA result.

Should percent free PSA be used in the decision to perform initial prostate biopsy in men with moderately elevated PSA?

Jody A. Charnow April 06, 2012

A recently published paper reported on the development of an improved nomogram for predicting outcomes of initial biopsies based on readily available clinical information.

PSA Screening Lowers Prostate Cancer Mortality

Jody A. Charnow March 16, 2012

PSA-based screening significantly decreases the risk of dying from prostate cancer (PCa), according to updated results of a large European study.

Survey: Leading Urologists Favor Routine PSA Tests

Stephan Cho October 31, 2011

Most leading urologists recommend routine PSA testing for men aged 50 and older, despite a recent U.S. panel's recommendation, according to a survey by U.S. News World & Report.

Urologists Oppose U.S. Panel's Stance Against PSA Testing

Stephan Cho October 12, 2011

Urologists have voiced opposition to a national panel's recommendation that healthy men should not undergo PSA screening.

Prostate Cancer Drug May Delay Time to Second-Line Treatment

John Schieszer September 29, 2011

Degarelix may delay time to second-line therapy and improve PSA control and in men with advanced hormone-dependent prostate cancer, according to long-term data from an extension study. John Schieszer has the story in today's Medical Minute.

PSA Testing: Why the U.S. and Europe Differ

Delicia Honen Yard September 21, 2011

Solid evidence for a survival benefit from PSA screening for prostate cancer is lacking, but the practice is more widespread in the United States than in many European countries.

Factors May Identify Prostate Cancer Patients Most Likely to Benefit from Salvage Therapy

John Schieszer August 19, 2011

Patients with lower pre-salvage radical prostatectomy PSA levels and a lower post-radiation prostate biopsy Gleason score may have the highest probability for cure with salvage radical prostatectomy. John Schieszer explains in today's Medical Minute.

Earlier PSA Screening May Make Annual Testings Unnecessary

John Schieszer June 06, 2011

CHICAGO—PSA levels at the time of initial screening among men aged 44-50 years can accurately predict the risk that a man will die from prostate cancer (PCa) or develop metastatic PCa up to 30 years later, a Swedish study found.

MRI Scans May Improve PCa Recurrence at Low PSA Levels

John Schieszer May 03, 2011

Dynamic contrast enhanced (DCE) endorectal magnetic resonance imaging (MRI) of the pelvis may offer an effective method of assessing for local recurrence of prostate cancer (PCa) after prostatectomy, according to Texas researchers.

Flaws of PSA Screening Include Unnecessary Testing of Older Men

John Schieszer April 20, 2011

Prostate-specfic antigen (PSA)-based prostate cancer screening in the U.S. appears to have some serious flaws. It appears that many elderly men may be undergoing unnecessary PSA testing.

High PSA Velocity Alone Is Not Enough Reason for Biopsy

Delicia Honen Yard March 29, 2011

An analysis of 5,519 men undergoing biopsy in the control arm of the Prostate Cancer Prevention Trial uncovered no evidence to support the recommendation that men with high PSA velocity be biopsied in the absence of other indications, according to an online report in the Journal of the National Cancer Institute.

PSA Screening Lowers Metastasis Risk

Jody A. Charnow March 19, 2011

VIENNA—PSA screening for prostate cancer (PCa) decreases the risk of PCa-related metastatic disease, according to study findings presented at the European Association of Urology 26th annual congress.

Pomegranate Extract May Slow Prostate Cancer Advance

Jody A. Charnow February 18, 2011

ORLANDO—A pomegranate extract slowed progression of prostate cancer (PCa) in a study of men who had rising PSA levels after primary treatment for the malignancy.

Dutasteride May Lead to More Reliable PSA Screening

John Schieszer January 12, 2011

The PSA screening test for prostate cancer is far from perfect. However, a new study suggests the test may be more reliable in men taking dutasteride (Avodart®). John Schieszer explains in today's Medical Minute.

PSA Levels in Men Age 55-60

John Schieszer November 15, 2010

New data are suggesting that a baseline PSA level of 1 ng/mL at age 55 or 60 may mean men need no further screening. These finding may further tailor how the PSA test is used. John Schieszer has the latest in today's Medical Minute.

Obese Men Have Lower PSA-Driven Biopsy Rates

John Schieszer October 07, 2010

Syndicated medical journalist John Schieszer reports on new research showing that, among men who undergo PSA tests, those who are obese are significantly less likely to have a PSA level of 4 ng/mL or higher, a widely used criterion for undergoing a prostate biopsy.

PSA at Age 60 Predicts Prostate Cancer Death Risk

Jody A. Charnow October 01, 2010

PSA levels measured at age 60 predict a man's lifetime risk of metastasis and death from prostate cancer (PCa), according to a study published online in the British Medical Journal.

Baseline PSA Predicts Prostate Cancer Death Risk

Delicia Honen Yard September 24, 2010

Baseline PSA levels reliably and independently predicts death from prostate cancer, with a baseline reading of 4 ng/mL or higher linked with greater mortality risk.

Open Prostatectomy, TURP Are the Most Common BPH Surgeries

Prostatic Artery Embolization Eases BPH Symptoms

NSAIDs Do Not Protect Against BPH/LUTS

Optimal Sequencing of the New Prostate Cancer Drugs: An Interview with E. David Crawford, MD

Prostate Cancer Outcome Not Tied to Complementary Medicine

Vitamin D May Help Prostate Cancer Patients

Newsletters

Latest News
Latest CME
Ongoing Clinical Trials
Conference Highlights
Expert Q&A

Legal Issues

After Radical Prostatectomy, Patient Learns He Never Had Prostate Cancer

Is honesty always the best policy? That is the question that a urologist had to grapple with in this case.

Your Practice

The move from ICD-9-CM to ICD-10 is enough to strike fear into the hearts of physicians and staff alike. Making the leap from 14,000 codes to almost 69,000, topped with the huge cost to make that change, is understandably daunting.

Read more on
Coping with ICD-10

Have any practice management topics that you'd like us to cover?
Let us know.